Robert W. Baird Raises Medpace (NASDAQ:MEDP) Price Target to $454.00

Medpace (NASDAQ:MEDP) had its target price raised by Robert W. Baird from $446.00 to $454.00 in a research report released on Wednesday, Benzinga reports. They currently have an outperform rating on the stock.

MEDP has been the topic of a number of other reports. StockNews.com upgraded shares of Medpace from a hold rating to a buy rating in a research note on Tuesday. Deutsche Bank Aktiengesellschaft initiated coverage on Medpace in a research report on Monday, March 18th. They set a hold rating and a $395.00 price objective for the company. UBS Group raised Medpace from a neutral rating to a buy rating and boosted their price objective for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. Finally, Jefferies Financial Group raised Medpace from a hold rating to a buy rating and boosted their price objective for the stock from $340.00 to $450.00 in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $443.00.

Medpace Trading Up 1.6 %

Shares of MEDP opened at $395.93 on Wednesday. The firm has a market cap of $12.27 billion, a P/E ratio of 40.36, a price-to-earnings-growth ratio of 1.94 and a beta of 1.38. The company’s 50-day moving average price is $397.83 and its 200 day moving average price is $325.15. Medpace has a 12-month low of $189.30 and a 12-month high of $421.00.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. The company had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The business’s revenue for the quarter was up 17.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.27 earnings per share. Equities research analysts forecast that Medpace will post 11.23 earnings per share for the current year.

Insider Activity at Medpace

In other news, major shareholder Medpace Investors, Llc sold 50,000 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the completion of the sale, the insider now directly owns 5,539,947 shares of the company’s stock, valued at $2,170,274,237.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the sale, the vice president now owns 15,181 shares in the company, valued at $6,117,943. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the sale, the insider now owns 5,539,947 shares of the company’s stock, valued at approximately $2,170,274,237.25. The disclosure for this sale can be found here. Insiders sold 189,340 shares of company stock valued at $76,651,647 over the last three months. 20.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Rise Advisors LLC purchased a new position in Medpace in the first quarter worth $27,000. Mather Group LLC. purchased a new position in Medpace in the first quarter worth $28,000. Contravisory Investment Management Inc. purchased a new position in shares of Medpace in the fourth quarter valued at $26,000. RiverPark Advisors LLC purchased a new position in shares of Medpace in the fourth quarter valued at $26,000. Finally, Arcadia Investment Management Corp MI increased its position in shares of Medpace by 40.3% in the first quarter. Arcadia Investment Management Corp MI now owns 101 shares of the company’s stock valued at $41,000 after buying an additional 29 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.